Sanofi's Rezurock Expands Provincial Access in Canada

MT Newswires Live03:04

Sanofi (SNY) said Tuesday that Rezurock, or belumosudil, has been added to the provincial formularies in Canada's British Columbia and Ontario for adult and pediatric patients aged 12 and older with chronic graft-versus-host disease, or GVHD, who have not responded to at least two prior systemic therapies.

This follows Rezurock's coverage in Quebec since November 2025, the company said, adding that full reimbursement criteria are available on provincial and Canada Drug Agency websites.

Chronic GVHD is a serious complication that can occur after a stem cell transplant, when donor cells attack the patient's body, the company said.

Price: 47.46, Change: +0.19, Percent Change: +0.40

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608804751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 03:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608804751","market":"fut","top_or_hot":-1,"title":"Sanofi's Rezurock Expands Provincial Access in Canada","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Tuesday that Rezurock, or belumosudil, has been added to the provincial formularies in Canada's British Columbia and Ontario for adult and pediatric patients aged 12 and older with chronic graft-versus-host disease, or GVHD, who have not responded to at least two prior systemic therapies.</p><p>This follows Rezurock's coverage in Quebec since November 2025, the company said, adding that full reimbursement criteria are available on provincial and Canada Drug Agency websites.</p><p>Chronic GVHD is a serious complication that can occur after a stem cell transplant, when donor cells attack the patient's body, the company said.</p><p>Price: 47.46, Change: +0.19, Percent Change: +0.40</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's Rezurock Expands Provincial Access in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's Rezurock Expands Provincial Access in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-04 03:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Tuesday that Rezurock, or belumosudil, has been added to the provincial formularies in Canada's British Columbia and Ontario for adult and pediatric patients aged 12 and older with chronic graft-versus-host disease, or GVHD, who have not responded to at least two prior systemic therapies.</p><p>This follows Rezurock's coverage in Quebec since November 2025, the company said, adding that full reimbursement criteria are available on provincial and Canada Drug Agency websites.</p><p>Chronic GVHD is a serious complication that can occur after a stem cell transplant, when donor cells attack the patient's body, the company said.</p><p>Price: 47.46, Change: +0.19, Percent Change: +0.40</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG1179.USD","symbol_name":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608804751","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608804751","pubTimestamp":1770145482,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sanofi  said Tuesday that Rezurock, or belumosudil, has been added to the provincial formularies in Canada's British Columbia and Ontario for adult and pediatric patients aged 12 and older with chronic graft-versus-host disease, or GVHD, who have not responded to at least two prior systemic therapies.This follows Rezurock's coverage in Quebec since November 2025, the company said, adding that full reimbursement criteria are available on provincial and Canada Drug Agency websites.Chronic GVHD is a serious complication that can occur after a stem cell transplant, when donor cells attack the patient's body, the company said.Price: 47.46, Change: +0.19, Percent Change: +0.40","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4007":"制药","SNY":"赛诺菲安万特","SNYNF":"Sanofi","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"赛诺菲的Rezurock扩大了加拿大省级准入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"SNYNF":1.5},"content_text":"Sanofi (SNY) said Tuesday that Rezurock, or belumosudil, has been added to the provincial formularies in Canada's British Columbia and Ontario for adult and pediatric patients aged 12 and older with chronic graft-versus-host disease, or GVHD, who have not responded to at least two prior systemic therapies.This follows Rezurock's coverage in Quebec since November 2025, the company said, adding that full reimbursement criteria are available on provincial and Canada Drug Agency websites.Chronic GVHD is a serious complication that can occur after a stem cell transplant, when donor cells attack the patient's body, the company said.Price: 47.46, Change: +0.19, Percent Change: +0.40","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608804751","isCrawlerRequest":true}